To date, only Microsatellite unstable (MSI)-H tumors and PD-L1-positive Cervical Cancer (CC) have received Food and Drug Association (FDA) approval for treatment with immune checkpoint inhibitors. The gene discussed is CD274; the disease is cervical carcinoma.